Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
European Society for Medical Oncology (ESMO) GI
Jun 28
- Jul 1, 2023
Results from an expanded phase 1 trial of botensilimab, a multifunctional anti-CTLA-4, plus balstilimab(anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer
Bullock, et al.
Filter by
Zalifrelimab (CTLA-4 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 1
- Jun 5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN1884, an Anti-CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies: Dose Selection for Combination with PD-1 Blockade.
Wilky, et al.
Balstilimab (PD-1 Antagonist)
American Society of Clinical Oncology (ASCO)
Jun 1
- Jun 5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation.
Moore, et al.
Zalifrelimab (CTLA-4 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors.
de Souza, et al.
Balstilimab (PD-1 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors.
de Souza, et al.
INCAGN2385 (LAG-3 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies.
Savitsky, et al.
INCAGN2390 (TIM-3 Antagonist)
American Association for Cancer Research (AACR)
Apr 14
- Apr 18, 2018
INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3.
Waight, et al.